Phathom Pharmaceuticals Stock Investor Sentiment

PHAT Stock  USD 8.93  0.36  3.88%   
Slightly above 67% of Phathom Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Phathom Pharmaceuticals stock suggests that many investors are alarmed at this time. Phathom Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Phathom Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Phathom Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Phathom Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
How Will the Market React to Phathom Pharmaceuticals Inc Stock Getting a Bearish Rating - InvestorsO...
Google News at Macroaxis
over six months ago at news.google.com         
Phathom Pharmaceuticals Stock Rating Reaffirmed by Needham Company LLC - AmericanBankingNEWS
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Phathom Pharmaceuticals Receives Buy Rating from Needham Company LLC
news
over six months ago at news.google.com         
Premarket Mover Phathom Pharmaceuticals Inc Down 2.37 percent - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
Do Traders Think Phathom Pharmaceuticals Inc Can Keep Climbing Friday - InvestorsObserver
Google News at Macroaxis
over six months ago at simplywall.st         
Insider Traders Lose US55k As Phathom Pharmaceuticals Drops
Simply Wall St News at Macroaxis
over six months ago at investing.com         
Phathom Pharmaceuticals gains Express Scripts formulary placement
Investing News at Macroaxis
over six months ago at news.google.com         
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelati...
Google News at Macroaxis
over six months ago at news.google.com         
Phathom Pharmaceuticals Stock Rating Reaffirmed by Needham Company LLC - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Phathom Pharmaceuticals, Inc. Receives Average Rating of Moderate Buy from Brokerages - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Long Term Trading Analysis for - Stock Traders Daily
Google News at Macroaxis
over six months ago at globenewswire.com         
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Confe...
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
With 47 percent ownership, Phathom Pharmaceuticals, Inc. has piqued the interest of institutional in...
Yahoo News
over six months ago at seekingalpha.com         
Sale by Takeda Pharmaceutical Co Ltd of 3703703 shares of Phathom Pharmaceuticals
seekingalpha News
over six months ago at news.google.com         
Molly Henderson Sells 6307 Shares of Phathom Pharmaceuticals, Inc. Stock - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Phathom Pharmaceuticals that are available to investors today. That information is available publicly through Phathom media outlets and privately through word of mouth or via Phathom internal channels. However, regardless of the origin, that massive amount of Phathom data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Phathom Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Phathom Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Phathom Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Phathom Pharmaceuticals alpha.

Phathom Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 2159 shares by Henderson Molly of Phathom Pharmaceuticals at 9.6 subject to Rule 16b-3
09/25/2024
2
Phathoms Voquezna A Breakthrough Drug Facing Marketing Challenges - Seeking Alpha
09/27/2024
3
Phathom Pharmaceuticals, Inc. Announces Encouraging Data for VOQUEZNA at ACG 2024
10/28/2024
4
Phathom Pharmaceuticals Scheduled to Post Quarterly Earnings on Thursday
11/06/2024
5
Phathom Pharmaceuticals maintains 28 target, Buy rating
11/07/2024
6
Phathom Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and ...
11/08/2024
7
Phathom Pharmaceuticals Upgraded to Buy Heres What You Should Know
11/19/2024
8
Down -54.05 percent in 4 Weeks, Heres Why Phathom Pharmaceuticals Looks Ripe for a Turnaround - MSN
12/09/2024

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.